We found that dysregulated miR‐34a could change tumorigenesis and gefitinib resistance in NSCLC through Axl by affecting the related downstream signaling pathways of PI3K/AKT, MEK/ERK and JAK/STAT in vitro and in vivo. This evidence concerns the gene AXL and non-small cell lung carcinoma.